(Q38333145)

2 September 2017

1 reference

title

Minimal residual disease in multiple myeloma: bringing the bench to the bedside (English)

1 reference

2 September 2017

1 reference

7

Ola Landgren

1 reference

2 September 2017

1

Sham Mailankody

1 reference

Maryalice Stetler-Stevenson

2 September 2017

6

object named as

Maryalice Stetler-Stevenson

1 reference

2 September 2017

Neha Korde

2

1 reference

2 September 2017

Alexander M Lesokhin

3

1 reference

2 September 2017

Nikoletta Lendvai

4

1 reference

2 September 2017

Hani Hassoun

5

1 reference

2 September 2017

language of work or name

English

0 references

publication date

27 January 2015

1 reference

Nature Reviews Clinical Oncology

2 September 2017

published in

1 reference

2 September 2017

volume

12

1 reference

2 September 2017

issue

5

1 reference

2 September 2017

page(s)

286-295

1 reference

Improved long-term survival in multiple myeloma up to the age of 80 years

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Dilemmas in treating smoldering multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Minimal residual disease: what are the minimum requirements?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Cell-free nucleic acids as biomarkers in cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Analysis of circulating tumor DNA to monitor metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Initial genome sequencing and analysis of multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Multiple myeloma cancer stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Phenotypic detection of clonotypic B cells in multiple myeloma by specific immunoglobulin ligands reveals their rarity in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

Next-generation sequencing of peripheral B-lineage cells pinpoints the circulating clonotypic cell pool in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.239

High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25622976

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2014.239

1 reference

2 September 2017

1 reference